Sengenics, a leading molecular diagnostics and research company in the region, today announced the launch of VisibiliT, Sequenom's new low-cost, non-invasive, prenatal test. After successfully launching the MaterniT21 prenatal test in November 2012 in Singapore and Malaysia, Sequenom has chosen Sengenics... - September 02, 2014
Gribbles Pathology and Sengenics today announced an exclusive partnership to deliver genetic-based clinical tests in Malaysia.
The aim of the partnership, between Gribbles, one of Asia and Australasia’s leading private pathology laboratories and Sengenics, a leading genetic diagnostics company... - May 09, 2013
Sengenics, a leading genetic diagnostics company and Parkway Laboratory Services, the premier private laboratory services provider in Singapore, and part of the Parkway Pantai group, the largest private healthcare provider in the region, announced today that they have entered into an exclusive partnership... - April 25, 2013
Sengenics today announced that it has signed an agreement with Oxford Gene Technology (OGT) to enable the launch of a global cancer biomarker discovery and clinical trial immuno-response monitoring service. The service will be based upon OGT’s proprietary full-length functional protein array platform.
Sengenics... - February 25, 2013
Sengenics, Asia’s 1st Genetic Diagnostics Company, today announced that it has entered into an exclusive agreement with The Sequenom Center for Molecular Medicine (Sequenom CMM), to launch and promote its MaterniT21 PLUS non-invasive prenatal testing service in Malaysia and Singapore.
Sengenics... - November 13, 2012
Sengenics today announced the introduction of a new microarray based genetic diagnostics test into Asia. The microarray used for the test was designed by Oxford Gene Technology (OGT), UK in conjunction with Emory Genetics, USA.
Microarrays are now recommended as the most effective method for diagnosing... - July 26, 2011